Conformational Selection is an industry-leading theory for drug development proposed by Fapon Digiwiser’s Founder and Chief Scientist, Dr. Buyong MA. By thoroughly analyzing drug targets and the conformational changes of biological molecules, combined with the regulation of biological activities, we design better biologics. Integrating molecular simulation and AI technologies to understand and regulate the conformational selection of drug molecules and their targets forms the cornerstone of Fapon Digiwiser’s innovative drug development process. This approach is a key driver of our technology innovation.
